Sign In
Buy NTLA
$13.02
-0.110 (-0.84%)
At Close: Jun 03, 2026
Intellia (NTLA) Miss Earnings & Revenues Estimates in Q4
01:32am, Friday, 26'th Feb 2021
Intellia (NTLA) miss earnings and revenues estimates in the fourth quarter of 2020. Stock up.
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2020 Earnings and Company Updates
07:30am, Thursday, 18'th Feb 2021
CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology
What's in the Cards for Intellia (NTLA) This Earnings Season?
11:25am, Tuesday, 16'th Feb 2021
Intellia Therapeutics (NTLA) is likely to discuss the progress of its pipeline candidate on its fourth-quarter earnings call.
A Highly Specialized Gene Editing Stock with a Clear Pathway to Big Gains
09:44am, Friday, 29'th Jan 2021
It's been a long, long journey… but we are finally at the point where genomics is ready to change the world. The post A Highly Specialized Gene Editing Stock with a Clear Pathway to Big Gains appear
Intellia, Editas: How Are Gene Editing Stocks Faring?
11:00am, Thursday, 28'th Jan 2021
Gene-editing technology is used to insert, edit, or delete a gene from an organism's genome, and shows promise in treating medical conditions ranging from cancer to rare genetic conditions. Our indica
Beam, SpringWorks Biggest Gainers on BioSpace List
06:14pm, Tuesday, 19'th Jan 2021
Among the public companies that made the BioSpace list of the top up and coming life sciences firms in 2019 and 2020, the majority have seen gains in their share prices. Given this metric, investors m
7 CRISPR Stocks for the Future of Medicine
06:12pm, Friday, 15'th Jan 2021
Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century. The post 7 CRISPR Stocks for the Future of Medicine appeared first on
CRISPR, Editas, Intellia: Gene Editing Stocks To Play The Next Revolution In Medicine
10:00am, Monday, 11'th Jan 2021
Gene editing has emerged as a promising biotech theme. The technology is used to insert, edit, or delete a gene from an organism's genome, helping to replace the defective genes responsible for a medi
Portfolio Manager Thinks Gene-Editing Stocks Could Outperform Tesla
05:36pm, Friday, 08'th Jan 2021
A leading portfolio manager recently told Bloomberg Television that gene-editing companies may turn out to be better investment opportunities than Tesla Inc. (NASDAQ:TSLA).
Is Intellia a Buy after its early success this year?
10:56am, Friday, 08'th Jan 2021
We all know about the red-hot sectors like electric vehicles, SPAC IPOs, and cloud based software, but the real investors know that the next industry to truly take off is in biotech, specifically in g
CRISPR Gene Editing Stocks Up After Intellia's Pipeline Update
09:47am, Friday, 08'th Jan 2021
Shares of Intellia were up as the update on its gene-editing drugs excited investors. The news also pushed up stocks of companies making gene-editing drugs, FATE, CRSP, EDIT, using CRISPR technology.
Why Intellia Therapeutics Stock Is Soaring Today
01:05pm, Thursday, 07'th Jan 2021
Investors are looking forward to what could be a great year for the biotechnology company.
3 Biotech Technological Developments to Watch Out For in 2021
09:47am, Thursday, 07'th Jan 2021
Here we discuss three booming technological developments in the biotech sector, which can capture investor attention in 2021
5 Disruptive Biotech Stocks With Solid Long-Term Potential
10:41am, Monday, 04'th Jan 2021
Here we discuss five biotech stocks - EDIT, VRTX, NTLA, CBAY, MRNS - that could prove to be great investments in the long run.
Why CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics Stocks Are Sinking Today
12:27pm, Tuesday, 29'th Dec 2020
The gene-editing stocks are being pulled down by a broader biotech sell-off.
